Washington: US have prohibited the Indian Pharmaceutical company Ranbaxy from producing and distributing drugs for the American market.

The Indian Pharmaceutical giant has a drug manufacturing division at Toansa in Punjab.

By an order FDA has prohibited Ranbaxy from distributing drugs in the US market.
They had been manufacturing medicines using active pharmaceutical ingredients (API) in Toansa as well as the drugs from Ranbaxy’s Ohm Laboratories facility in New Jersey.

Recently Ranbaxy Laboratories has also been prohibited from manufacturing API at its Toansa facility for FDA-regulated drug products.

They have been asked to stop exporting of API from Toansa to the US for any purpose and providing API to other companies including other Ranbaxy facilities which make products for American consumers.